trial

A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder

NCTId NCT06878833
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Withdrawn
Enrollment 0 (actual)
Sponsored by Lyndra Inc.
Primary completion 2026-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2025-04-18
Primary completion
2026-12-31
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Risperidone

Sponsors

Lyndra Inc.Lead Sponsor

Investigators

1
Nayana NagarajStudy Director

Sites

0 total

Linked catalysts

1
A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone — primary completion2026-12-31

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE3
Primary Completion Date
2026-12-31
Status
WITHDRAWN
relationships
The graph out of here
drug
Risperidone
drug
lead_sponsor
Lyndra Inc.
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Nayana Nagaraj
person